TY - JOUR
T1 - Mu opioid receptor 1 (MOR-1) expression in colorectal cancer and oncological long-term outcomes
T2 - A five-year retrospective longitudinal cohort study
AU - Díaz-Cambronero, Oscar
AU - Mazzinari, Guido
AU - Giner, Francisco
AU - Belltall, Amparo
AU - Ruiz-Boluda, Lola
AU - Marqués-Marí, Anabel
AU - Sánchez-Guillén, Luis
AU - Eroles, Pilar
AU - Cata, Juan Pablo
AU - Argente-Navarro, María Pilar
N1 - Publisher Copyright:
© 2020 by the authors. Licensee MDPI, Basel, Switzerland.
PY - 2020/1
Y1 - 2020/1
N2 - Preclinical evidence has shown increased expression of mu opioid receptor 1 (MOR-1) in colorectal cancer although its association with disease-free and overall survival (DFS and OS) has not been investigated. We hypothesized that MOR-1 was overexpressed in tumor samples compared to normal tissue and this was associated with decreased DFS and OS. We carried out a retrospective study assessing the association of MOR-1 tumor expression with long-term outcomes by immunohistochemistry in normal and tumor samples from 174 colorectal cancer patients. The primary endpoint was five years of DFS. Secondary endpoints were five years of OS, the difference in MOR-1 expression between normal and tumor tissue and the occurrence of postoperative complications. Multivariable Cox regression showed no significant association between MOR-1 expression and DFS (HR 0.791, 95% CI 0.603–1.039, p = 0.092). MOR-1 expression was higher in tumor tissue compared to non-tumor tissue. No associations were found between MOR-1 expression and OS or postoperative complications. These findings suggest that although MOR-1 is over-expressed in colorectal cancer samples there is no association to increased risk of recurrence or mortality. Future studies are warranted to elucidate the role of cancer stage, genetic polymorphism, and quantitative assessment of MOR-1 over-expression on long-term outcomes in colorectal cancer.
AB - Preclinical evidence has shown increased expression of mu opioid receptor 1 (MOR-1) in colorectal cancer although its association with disease-free and overall survival (DFS and OS) has not been investigated. We hypothesized that MOR-1 was overexpressed in tumor samples compared to normal tissue and this was associated with decreased DFS and OS. We carried out a retrospective study assessing the association of MOR-1 tumor expression with long-term outcomes by immunohistochemistry in normal and tumor samples from 174 colorectal cancer patients. The primary endpoint was five years of DFS. Secondary endpoints were five years of OS, the difference in MOR-1 expression between normal and tumor tissue and the occurrence of postoperative complications. Multivariable Cox regression showed no significant association between MOR-1 expression and DFS (HR 0.791, 95% CI 0.603–1.039, p = 0.092). MOR-1 expression was higher in tumor tissue compared to non-tumor tissue. No associations were found between MOR-1 expression and OS or postoperative complications. These findings suggest that although MOR-1 is over-expressed in colorectal cancer samples there is no association to increased risk of recurrence or mortality. Future studies are warranted to elucidate the role of cancer stage, genetic polymorphism, and quantitative assessment of MOR-1 over-expression on long-term outcomes in colorectal cancer.
KW - Colon cancer
KW - Disease free survival
KW - Immunohistochemistry
KW - Mu opioid receptors
KW - Perioperative medicine
KW - Perioperative opioid
UR - http://www.scopus.com/inward/record.url?scp=85078231089&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85078231089&partnerID=8YFLogxK
U2 - 10.3390/cancers12010134
DO - 10.3390/cancers12010134
M3 - Article
C2 - 31948099
AN - SCOPUS:85078231089
SN - 2072-6694
VL - 12
JO - Cancers
JF - Cancers
IS - 1
M1 - 134
ER -